Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413374 · ClinicalTrials.gov registry record · NA

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

A NA study of Pulmonary Embolism and Deep Vein Thrombosis, sponsored by Brigham and Women's Hospital.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT00413374 is a NA study of Pulmonary Embolism and Deep Vein Thrombosis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants, below the 3,058-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00413374, a NA study of Pulmonary Embolism and Deep Vein Thrombosis, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To investigate the efficacy and safety of once daily enoxaparin as a "bridge" to warfarin for the outpatient treatment of acute deep venous thrombosis or pulmonary embolism.

Interventions

  • DRUG Enoxaparin

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-05
Est. Completion 2008-12
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT00413374

The ClinicalTrials.gov registry entry for NCT00413374 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,058-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Embolism appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.

NCT00413374 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00413374 about?

NCT00413374 is a clinical study titled "Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism". To investigate the efficacy and safety of once daily enoxaparin as a "bridge" to warfarin for the outpatient treatment of acute deep venous thrombosis or pulmonary embolism.

What is the current status of trial NCT00413374?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2006-05. Estimated completion is 2008-12.

What conditions does trial NCT00413374 study?

This clinical trial studies the following conditions: Pulmonary Embolism, Deep Vein Thrombosis.

What interventions are being tested in trial NCT00413374?

The interventions under investigation include: Enoxaparin (DRUG).

Who is sponsoring clinical trial NCT00413374?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00413374 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.